Barclays
PRPH

Barclays’s ProPhase Labs PRPH Stock Holding History

Barclays’s Portfolio PRPH Stock Details PRPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10
Closed -$39 – 5678
2025
Q2 		$39 Sell
10
-1,247
-99% -$4.17K ﹤0.01% 5126
2025
Q1 		$5.08K Buy
+1,257
New +$5.77K ﹤0.01% 4937
2024
Q4 		– Sell
-1,177
Closed -$28.5K – 5436
2024
Q3 		$28.5K Hold
1,177
– – ﹤0.01% 4848
2024
Q2 		$49.2K Buy
+1,177
New +$61.7K ﹤0.01% 4218
2023
Q3 		– Sell
-15
Closed -$1.07K – 4680
2023
Q2 		$1.07K Buy
+15
New +$1.22K ﹤0.01% 4357
2021
Q2 		– Sell
-50
Closed -$4K – 5040
2021
Q1 		$4K Buy
+50
New +$4.8K ﹤0.01% 4503
2020
Q3 		– Sell
-2
Closed – – 5496
2020
Q2 		$0 Buy
+2
New +$33 ﹤0.01% 6107
2019
Q2 		– Sell
-6
Closed – – 7190
2019
Q1 		$0 Buy
+6
New +$185 ﹤0.01% 7254
2018
Q2 		– Sell
-1
Closed – – 7215
2018
Q1 		$0 Buy
+1
New +$25 ﹤0.01% 7266

Other funds holding PRPH

SC
Sykon Capital Harrison, New York $325M AUM 19.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $412M AUM 15.82% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's PRPH Position: Q3 2025 in Review

Barclays sold out of ProPhase Labs (PRPH) in Q3 2025, closing a stake of 10 shares — an estimated $39 sold.

Barclays first reported a position in PRPH in Q1 2018 and held it in 9 quarters. The position peaked at $49.2K in Q2 2024. 28 funds tracked by Wall St. Rank hold PRPH as of Q3 2025.

  • Barclays reported no remaining ProPhase Labs position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 10 ProPhase Labs shares in Q3 2025, an estimated $39.
  • Barclays first reported a position in ProPhase Labs in Q1 2018 and held it in 9 quarters.
  • Barclays's ProPhase Labs position peaked at $49.2K in Q2 2024.
  • 28 funds tracked by Wall St. Rank held ProPhase Labs as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.